Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis
- PDF / 899,878 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 23 Downloads / 152 Views
ORIGINAL ARTICLE
Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis Whitney W. Woodmansee1,2 Murray B. Gordon3 Mark E. Molitch4 Adriana G. Ioachimescu5 Don W. Carver6 Beloo Mirakhur7 David Cox7 Roberto Salvatori8 ●
●
●
●
●
●
●
1234567890();,:
1234567890();,:
Received: 1 November 2017 / Accepted: 21 April 2018 © The Author(s) 2018
Abstract Purpose This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide, LAN) Depot for Acromegaly (SODA) registry. Methods Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed. Results There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9%) vs female patients (32.0%; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8%), followed by gonadotropin deficiency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3% vs 80.6%; p = 0.033). Conclusions Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients. Keywords Acromegaly Comorbidities Extended-Release Lanreotide Depot/Autogel Observational Study Registry ●
●
* Whitney W. Woodmansee [email protected]fl.edu 1
Division of Endocrinology, Diabetes and Metabolism, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA
2
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital/Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA
3
4
Allegheny Neuroendocrinology Center, Division of Endocrinology, Allegheny General Hospital, 420 E North Ave, Suite 205, Pittsburgh, PA 15212, USA Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, Chicago, IL 60611, USA
●
●
●
5
Department of Medicine, Division of Endocrinology, Metabolism and Lipids, and Department of Neurosurgery, Emory University School of Medicine, 1365
Data Loading...
